Immortal Dragons, a purpose-driven longevity fund based in Singapore, is focused on funding innovative biotech and life extension projects.

Founded by Boyang Wang, the fund aims to support underfunded longevity initiatives, prioritizing impact over traditional economic returns.

In nearly two years, the fund has made over ten investments, managing a total of $14 million, and is dedicated to groundbreaking projects in the longevity space.

The fund specifically targets unique 'replacement' strategies in anti-aging, such as xenotransplantation and 3D bioprinting, rather than conventional repair methods.

Wang's background in gene therapy and tissue banking reflects a risk-tolerant investment philosophy aimed at pioneering longevity biotech initiatives.

He emphasizes the need for an economic 'flywheel' in longevity research to attract more investment and talent, believing the sector is at a critical inflection point.

Immortal Dragons also encourages collaboration between Eastern and Western longevity communities, recognizing the diverse cultural attitudes towards aging and life extension.

While quantifying the impact of investments is challenging, the fund evaluates projects based on rarity and their potential to inspire the public.

Wang believes in the influence of role models in the longevity sector, citing Larry Ellison as an example of individual success that could drive further investment.

His personal experiences with healthcare and philosophical beliefs about life's meaning have significantly motivated his interest in longevity.

The potential of AI in longevity, particularly in drug discovery and medical diagnostics, is promising, although concerns about accountability persist.

Critics argue that the fund's focus on high-risk, high-reward projects may be unrealistic given the availability of more immediate health solutions.

Additionally, Immortal Dragons is open to supporting non-biotech projects that align with their mission, showcasing a flexible approach to funding.